Kairos Pharma, Ltd.
AMEX: KAPA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John S. Yu
- Employees
- 1
- Headquarters
- Los Angeles, United States
- IPO year
- 2024
- Market cap
- $9.2M
- Website
- https://kairospharma.com
Loading KAPA…
Loading profile data…Frequently asked questions about KAPA
What does Kairos Pharma, Ltd. (KAPA) do?
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initial...
Where does KAPA trade?
Kairos Pharma, Ltd. (KAPA) trades on the New York Stock Exchange American.
What sector is KAPA in?
Kairos Pharma, Ltd. (KAPA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kairos Pharma, Ltd.?
John S. Yu is the chief executive officer of Kairos Pharma, Ltd. (KAPA).
Where is Kairos Pharma, Ltd. headquartered?
Kairos Pharma, Ltd. is headquartered in United States.
Does KAPA pay a dividend?
Kairos Pharma, Ltd. (KAPA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KAPA go public?
Kairos Pharma, Ltd. (KAPA) completed its initial public offering in 2024.